Total raised
—
Stage
Pre-Funding
Founded
2018
Headcount
1-10
HQ
Ness Ziona
Sector
Health Tech & Life Sciences
About
TeloCure aims to develop a gene therapy for hoyeraal-hreidarsson syndrome, an ultra-rare disease characterized by excessively short telomeres which is considered a severe form of dyskeratosis congenita.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is TeloCure's primary focus?
- TeloCure aims to develop a gene therapy for Hoyeraal-Hreidarsson Syndrome, an ultra-rare disease characterized by excessively short telomeres.
- When was TeloCure founded?
- TeloCure was founded in July 2018.
- What is the current operational status of TeloCure?
- TeloCure is currently inactive, having ceased operations in October 2019.
- Where is TeloCure headquartered?
- TeloCure is headquartered in Ness Ziona, Israel.
- What is TeloCure's primary sector?
- TeloCure's primary sector is Health Tech & Life Sciences, specifically focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development.
- Who is the founder of TeloCure?
- Noam Diamant is identified as the founder of TeloCure.
- What is TeloCure's employee count?
- TeloCure has an employee count in the 1-10 range, with one identified team member.
- What is TeloCure's current funding stage?
- TeloCure is in the Pre-Funding stage, with a total raised amount of $0 USD.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Tags
stealthmodeneurologygenetic-disordersrare-diseasesimmunotherapytherapeutics